Stay updated on Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page now presents the completed Phase III study record comparing trastuzumab emtansine with lapatinib plus capecitabine in Chinese participants with HER2-positive advanced or metastatic breast cancer. It includes eligibility requirements, study locations, outcome measures, and a related publication.
    Difference
    60%
    Check dated 2026-11-10T16:13:02.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.2 to v3.8.0, while the study record remains unavailable behind a 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-11-03T16:42:59.000Z thumbnail image
  3. Check
    25 days ago
    Change Detected
    Summary
    The error page gained an NIH-wide notice about a terminology transition from “Artificial Intelligence” to “Super Intelligence.” The displayed site revision advanced from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T19:21:02.000Z thumbnail image
  4. Check
    39 days ago
    Change Detected
    Summary
    The site footer revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T20:52:25.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error, replacing the full study record. As a result, key information about the trial's design, locations, eligibility criteria, and contacts is temporarily unavailable to users.
    Difference
    18%
    Check dated 2026-09-22T22:19:25.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.7.0, replacing Revision: v3.6.6. This indicates an update to the page's release version.
    Difference
    0.1%
    Check dated 2026-09-15T20:53:14.000Z thumbnail image

Stay in the know with updates to Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial page.